Manufacturing and evaluation of parenterals MCQs With Answer

Manufacturing and evaluation of parenterals MCQs With Answer is designed for M. Pharm students to strengthen conceptual clarity and problem-solving skills in sterile dosage form development. This quiz focuses on advanced aspects of parenteral manufacturing: aseptic processing vs terminal sterilization, depyrogenation, cleanroom design and environmental control, WFI production, sterile filtration, and lyophilization. It also covers critical evaluation tests such as sterility, bacterial endotoxins (LAL), particulate matter, container–closure integrity, and formulation considerations like isotonicity, buffering, antioxidants, and solubilization strategies. Each question targets exam-oriented thinking while aligning with Modern Pharmaceutics (MPH 103T) outcomes. Use these MCQs to assess your mastery, identify weak areas, and prepare effectively for theory, viva, and practical assessments.

Q1. In terminal sterilization of parenterals, the typical sterility assurance level (SAL) targeted for a finished product is:

• 10^-3
• 10^-6
• 10^-12
• 10^-1

Correct Answer: 10^-6

Q2. The D-value used in moist heat sterilization kinetics is defined as:

• The time to reduce bioburden by 99.99% at a reference temperature
• The temperature increase needed to reduce the D-value by one log
• The time required at a specified temperature to achieve a one-log (90%) reduction in viable organisms
• The equivalent exposure at 121°C for a given cycle

Correct Answer: The time required at a specified temperature to achieve a one-log (90%) reduction in viable organisms

Q3. The z-value in sterilization process design represents:

• The slope of the survivor curve at the reference temperature
• The time at 121°C required to achieve SAL 10^-6
• The temperature increase needed to reduce the D-value by a factor of 10
• The cumulative lethality at 121°C

Correct Answer: The temperature increase needed to reduce the D-value by a factor of 10

Q4. In moist heat sterilization, F₀ is best described as:

• Cumulative equivalent lethality at 121°C (z = 10°C) integrating the time–temperature profile
• The time at 100°C required to reduce spores by 6 logs
• A measure of filter retention efficiency for bacteria
• The time to reach equilibrium between chamber and load temperatures

Correct Answer: Cumulative equivalent lethality at 121°C (z = 10°C) integrating the time–temperature profile

Q5. A standard dry-heat depyrogenation cycle for glassware in parenteral manufacturing typically uses:

• 121°C for 15 minutes
• 160°C for 2 hours
• 105°C for 60 minutes
• 250°C for not less than 30 minutes

Correct Answer: 250°C for not less than 30 minutes

Q6. According to current pharmacopeial expectations, Water for Injection (WFI) for parenteral manufacturing may be produced by:

• Only distillation, no exceptions
• Distillation or equivalent membrane processes with appropriate design, monitoring, and biofilm control
• Deionization alone followed by UV treatment
• Carbon filtration followed by microfiltration

Correct Answer: Distillation or equivalent membrane processes with appropriate design, monitoring, and biofilm control

Q7. For filterable aqueous parenteral products, the compendial sterility test method of choice is:

• Direct inoculation method
• Membrane filtration method
• Agar diffusion method
• Pour plate method

Correct Answer: Membrane filtration method

Q8. The principle of the gel-clot Limulus Amebocyte Lysate (LAL) test for endotoxins is based on:

• Chromogenic substrate cleavage producing a colored product
• Increase in turbidity measured spectrophotometrically
• Endotoxin-triggered proteolytic cascade causing clot formation
• Fluorescence quenching by lipid A

Correct Answer: Endotoxin-triggered proteolytic cascade causing clot formation

Q9. The primary compendial method for quantifying subvisible particulate matter in small-volume injections is:

• Microscopic particle count test
• Light obscuration particle count test
• Nephelometry
• Visual inspection under black-and-white background

Correct Answer: Light obscuration particle count test

Q10. High-Efficiency Particulate Air (HEPA) filters used in aseptic processing areas typically remove at least:

• 95% of particles ≥0.5 μm
• 99.97% of particles ≥0.3 μm
• 99.9% of particles ≥1.0 μm
• 90% of particles ≥0.1 μm

Correct Answer: 99.97% of particles ≥0.3 μm

Q11. The pore size most commonly used for sterilizing-grade filtration of parenteral solutions is:

• 1.2 μm
• 0.45 μm
• 0.22/0.20 μm
• 0.05 μm

Correct Answer: 0.22/0.20 μm

Q12. Which of the following is a deterministic container–closure integrity test (CCIT) method?

• Dye ingress test
• Bubble emission in water bath
• Vacuum decay test
• Blue fluorescein penetration

Correct Answer: Vacuum decay test

Q13. For parenteral solutions requiring the highest hydrolytic resistance, the preferred glass container type is:

• Type II treated soda-lime glass
• Type I borosilicate glass
• Type III soda-lime glass
• Type NP non-parenteral glass

Correct Answer: Type I borosilicate glass

Q14. The most appropriate sterilization method for elastomeric closures (vial stoppers) after washing and siliconization is:

• Dry heat at 250°C
• Steam sterilization (autoclaving) at 121–134°C
• Gamma irradiation at 50 kGy
• Ethylene oxide without aeration

Correct Answer: Steam sterilization (autoclaving) at 121–134°C

Q15. In isotonicity adjustment, the sodium chloride equivalent (E-value) of a drug is defined as:

• The grams of drug equivalent in tonicity to 1 g of NaCl
• The grams of NaCl equivalent in tonicity to 1 g of drug
• The molar concentration of drug required to match plasma osmolality
• The freezing point depression caused by 1% drug solution

Correct Answer: The grams of NaCl equivalent in tonicity to 1 g of drug

Q16. A key principle for buffer selection in parenteral formulations is to:

• Use the highest possible buffer concentration to resist pH change
• Use the lowest buffer capacity that maintains pH over shelf life to minimize tissue irritation
• Always choose phosphate buffers due to their strong buffering capacity
• Adjust pH post-sterilization only

Correct Answer: Use the lowest buffer capacity that maintains pH over shelf life to minimize tissue irritation

Q17. Which excipient is commonly used as a chelating agent to enhance antioxidant efficacy in aqueous parenterals?

• Sodium metabisulfite
• Butylated hydroxyanisole (BHA)
• Disodium edetate (EDTA)
• Alpha-tocopherol

Correct Answer: Disodium edetate (EDTA)

Q18. An example of a complexing agent used to improve the solubility of poorly soluble drugs in parenteral formulations is:

• Propylene glycol
• Polysorbate 80
• Hydroxypropyl-β-cyclodextrin
• Polyethylene glycol 400

Correct Answer: Hydroxypropyl-β-cyclodextrin

Q19. During lyophilization of parenterals, to prevent product collapse in primary drying, the product temperature should be maintained:

• Above the glass transition temperature (Tg′) for faster drying
• Below the collapse temperature (T_c) or eutectic melting point
• At the shelf temperature setpoint regardless of product resistance
• Above 0°C to avoid vial breakage

Correct Answer: Below the collapse temperature (T_c) or eutectic melting point

Q20. Which statement about Large Volume Parenterals (LVPs) is most accurate?

• LVPs are ≤100 mL and generally contain preservatives
• LVPs are >100 mL and typically do not contain antimicrobial preservatives
• LVPs are intended only for intramuscular use
• LVPs may be terminally sterilized only by filtration

Correct Answer: LVPs are >100 mL and typically do not contain antimicrobial preservatives

Download